Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

19.28
-0.2000-1.03%
Post-market: 19.280.00000.00%16:11 EDT
Volume:44.96K
Turnover:863.84K
Market Cap:983.93M
PE:-8.23
High:19.48
Open:19.22
Low:18.98
Close:19.48
Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
49
Office Location:
Bahnhofstrasse 20,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.